AltheRx Pharmaceuticals Inc.
Safe and highly selective therapy for IBS and OAB
This article was originally published in Start Up
Executive Summary
AltheRx Pharmaceuticals Inc. acquired its lead compound, solabegron, from GlaxoSmithKline in March 2011. Solabegron relaxes smooth muscles by stimulating beta-3 adrenoceptors, a novel mechanism compared with currently available treatments for overactive bladder and irritable bowel syndrome, the first two indications that AltheRx is targeting.